3LEYSEN JE, JANSSEN PM, MEGENS AA, et al. Risperidone: a novel antipsychotic with balanced serotonindopamine antagonism, receptor occupancy profile, and pharmacologic activity [ J ]. J Clln Psychiatry, 1994, 55 ( Suppl 1 ) : S5 - S12.
4RICHELSON E, SOUDER T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds [ J ]. Life Sci, 2000, 68 ( 1 ) : 29 - 39.
5DOLDER C, NELSON M, DEYO Z. Paliperidone for schizophre- nia[ J]. Am J Health Syst Pharm, 2008, 65 (5) : 403 -413.
6SCHNEIDER RA, LIZER MH. Apparent seizure and atrial fibril- lation associated with paliperidone[ J]. Am J Health Syst Pharm, 2008, 65(22) : 2122 -2125.
7KANE J, CANAS F, KRAMER M, et al. Treatment of schizo- phrenia with paliperidone extended-release tablets: a 6-week pla- cebo-controlled trial [ J ]. Schizophr Res, 2007, 90 ( 1 - 3 ) : 147 - 161.
8KRAMER M, SIMPSON G, MACIULIS V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, place- bo-controlledstudy[J]. J Clin Psychopharmacol, 2007, 27 (1) : 6 - 14.
9DAVIDSON M, EMSLEY R, KRAMER M, et al. Efficacy, safety and early response of ( paliperidone ER) : results of a 6- week, randomized, placebo-controlled study[ J]. Schizophr Res, 2007, 96(1 -3): 273 -274.
10Collaborative Working Group on Clinical Trial Evaluations. Ad- verse effects of the atypical antipsyehoties. Collaborative Working Group on Clinical Trial Evaluations [ J ]. J Clin Psychiatry, 1998, 59(Suppl 12) :S17 - S22.
